Drugs / TransMID
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00088400 | Jul 2004 → Nov 2005 | glioblastoma | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT00083447 | May 2004 → Mar 2006 | glioblastoma | Xenova Biomedix | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransMID | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083447 ↗ |
| Action | Deplete | “So the cancer cells are attached to the transferrin in TransMID, and the diphtheria poison kills them.” NCT00083447 ↗ |
| Modality | Protein / enzyme biologic | “TransMID is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin.” NCT00083447 ↗ |
| Route | Other | “Intratumoral/Interstitial Therapy” NCT00083447 ↗ |